NeuroSense Therapeutics Ltd. announced CFO Or Eisenberg will participate in the 5th Annual ROTH Healthcare Opportunities Conference. The event occurs September 29, 2026, in New York City.
Mr. Eisenberg will engage in one-on-one and small-group meetings with institutional investors.
Discussions will cover recent progress for PrimeC, the company's lead drug candidate. PrimeC treats amyotrophic lateral sclerosis (ALS).
Topics include recent clinical and regulatory developments. NeuroSense seeks potential regulatory approval in key markets. These markets include the U.S. and Canada.